Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies - Vermersch,P; Comi,G; Siva,A; Oreja-Guevara,C; Wiendl,H; Van,Wijmeersch B; Eralinna,J-P; Nicholas,R; Buffels,R; Bernasconi,C; Kuhelj,R (WILEY, 2018)